Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles

Claim 1

In a method for determining the location of a tumor which produces or is associated with a cytoplasmic, intracellular or cell-surface marker substance, which comprises injecting a human subject parenterally with a marker-specific antibody or antibody fragment labeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, or with a paramagnetic conjugate capable of detection with a magnetic resonance detector, and subsequently scanning with said device or detector to detect and locate the site or sites of uptake of said labeled antibody or antibody fragment by said tumor, the improvement comprising injecting said subject parenterally, at a time after injection of the marker-specific antibody or fragment sufficient to permit maximum selective uptake thereof by said tumor, and prior to scanning, with a second, non-labeled antibody or antibody fragment specific against said marker-specific antibody or fragment, in an amount sufficient to decrease the level of circulating labeled marker-specific antibody or fragment by 10-85% within 2-72 hours.

Claim 3

A method of detecting and localizing an infectious lesion which produces or is associated with a marker substance, which comprises the steps of: (a) injecting a human subject parenterally with a marker-specific antibody or antibody fragment labeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, or with a paramagnetic conjugate capable of detection with a magnetic resonance detector; (b) at a time after injection of said markerspecific antibody or fragment sufficient to permit maximum selective uptake thereof by said lesion, injecting said subject parenterally with a second antibody or fragment specific against said markerspecific antibody or fragment, in an amount sufficient to decrease the level of circulating labeled markerspecific antibody or fragment by 10-85% within 2-72 hours; and (c) subsequently scanning with said device or detector to detect and locate the site or sites of uptake of said labeled antibody or fragment by said lesion.

Claim 4

A method of detecting and localizing an infectious lesion which produces or is associated with a marker substance, which comprises the steps of: (a) injecting a human subject parenterally with a marker-specific antibody or antibody fragment labeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, or with a paramagnetic conjugate capable of detection with a magnetic resonance detector; (b) at a time after injection of said markerspecific antibody or fragment sufficient to permit maximum selective uptake thereof by said lesion, injecting said subject parenterally with a second antibody or fragment specific against said markerspecific antibody or fragment, in an amount sufficient to decrease the level of circulating labeled markerspecific antibody or fragment by 10-85% within 2-72 hours; and (c) subsequently scanning with said device or detector to detect and locate the site or sites of uptake of said labeled antibody or fragment by said lesion.

Claim 5

A method of tumor or infectious lesion therapy, comprising injecting a human subject having a tumor or infectious lesion, parenterally, with a therapeutic amount of primary antibody or antibody fragment specific against a marker produced by or associated with said tumor or lesion and labeled with a therapeutically effective radionuclide, boron addend, drug, toxin or a combination thereof; after a time sufficient to maximize selective uptake of the labeled primary antibody or antibody fragment by said tumor or lesion, injecting the subject parenterally with a second antibody or antibody fragment specific against said primary antibody or antibody fragment, or against said addend, drug or toxin, a carrier therefor or a chelating agent for said radionuclide, in an amount sufficient to decrease the level of circulating labeled primary antibody or antibody fragment by 10-85% within 2-72 hours; and, in the case of a boron-labeled primary antibody or antibody fragment, directing a beam of thermal neutrons at the site or sites of selective uptake of said labeled antibody or antibody fragment.

Claim 6

A method of tumor or infectious lesion therapy, comprising injecting a human subject having a tumor or infectious lesion, parenterally, with a therapeutic amount of primary antibody or antibody fragment specific against a marker produced by or associated with said tumor or lesion and labeled with a therapeutically effective radionuclide, boron addend, drug, toxin or a combination thereof; after a time sufficient to maximize selective uptake of the labeled primary antibody or antibody fragment by said tumor or lesion, injecting the subject parenterally with a second antibody or antibody fragment specific against said primary antibody or antibody fragment, or against said addend, drug or toxin, a carrier therefor or a chelating agent for said radionuclide, in an amount sufficient to decrease the level of circulating labeled primary antibody or antibody fragment by 10-85% within 2-72 hours; and, in the case of a boron-labeled primary antibody or antibody fragment, directing a beam of thermal neutrons at the site or sites of selective uptake of said labeled antibody or antibody fragment.

Claim 9

A method of detecting the localizing an infectious lesion which produces or is associated with a marker substance, which comprises the steps of: (a) injecting a human subject parenterally with a marker-specific antibody or antibody fragment labeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, or with a paramagnetic conjugate capable of detection with a magnetic resonance detector; (b) at a time after injection of said marker-specific antibody or fragment sufficient to permit maximum selective uptake thereof by said lesion, injecting said subject parenterally with a second antibody or fragment-specific against said marker-specific antibody or fragment, in an amount sufficient to increase the localization ratio by at least about 20% within 2-72 hours; and (c) subsequently scanning with said device or detector to detect and locate the site or sites of uptake of said labeled antibody or fragment by said lesion.

Claim 10

A method of detecting the localizing an infectious lesion which produces or is associated with a marker substance, which comprises the steps of: (a) injecting a human subject parenterally with a marker-specific antibody or antibody fragment labeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, or with a paramagnetic conjugate capable of detection with a magnetic resonance detector; (b) at a time after injection of said marker-specific antibody or fragment sufficient to permit maximum selective uptake thereof by said lesion, injecting said subject parenterally with a second antibody or fragment-specific against said marker-specific antibody or fragment, in an amount sufficient to increase the localization ratio by at least about 20% within 2-72 hours; and (c) subsequently scanning with said device or detector to detect and locate the site or sites of uptake of said labeled antibody or fragment by said lesion.

Claim 11

A method of tumor or infectious lesion therapy, comprising injecting a human subject having a tumor or infectious lesion, parenterally, with a therapeutic amount of a primary antibody or antibody fragment specific against a marker produced by or associated with said tumor or lesion and labeled with a therapeutically effective radionuclide, boron addend, drug, toxin or a combination thereof; after a time sufficient to maximize selective uptake of the labeled primary antibody or antibody fragment by said tumor or lesion, injecting the subject parenterally with a second antibody or antibody fragment specific against said primary antibody or antibody fragment, or against said addend, drug or toxin, a carrier therefor or a chelating agent for said radionuclide, in an amount sufficient to increase the therapeutic index by at least about 10%; and, in the case of a boron-labeled primary antibody or antibody fragment, directing a beam of thermal neutrons at the site or sites of selective uptake of said labeled antibody or antibody fragment.

Claim 12

A method of tumor or infectious lesion therapy, comprising injecting a human subject having a tumor or infectious lesion, parenterally, with a therapeutic amount of a primary antibody or antibody fragment specific against a marker produced by or associated with said tumor or lesion and labeled with a therapeutically effective radionuclide, boron addend, drug, toxin or a combination thereof; after a time sufficient to maximize selective uptake of the labeled primary antibody or antibody fragment by said tumor or lesion, injecting the subject parenterally with a second antibody or antibody fragment specific against said primary antibody or antibody fragment, or against said addend, drug or toxin, a carrier therefor or a chelating agent for said radionuclide, in an amount sufficient to increase the therapeutic index by at least about 10%; and, in the case of a boron-labeled primary antibody or antibody fragment, directing a beam of thermal neutrons at the site or sites of selective uptake of said labeled antibody or antibody fragment.

Claim 13

The method of either of claims 2 or 5, wherein said label is a radiolabel, and wherein prior to photoscanning, a second substance is injected into the subject, said second substance being radiolabeled with a radioisotope emitting at a different energy from the marker-specific antibody or antibody fragment label and capable of independent detection by said photoscanning device, the level of activity of said second substance being used to determine the background activity due to nontargeted specific antibody or antibody fragment, said background activity being subtracted from the total activity of the specific antibody or antibody fragment, whereby the activity of substantially only the targeted antibody or antibody fragment is determined.

Claim 15

The method of any of claims 2, 3, 5 or 6, wherein at least one of said labeled primary antibody or antibody fragment and said second antibody or antibody fragment is whole IgG.

Claim 16

The method of any of claims 2, 3, 5 or 6, wherein said second antibody is whole IgG or IgM.

Claim 17

The method of any of claims 2, 3, 5 or 6, wherein the molar ratio of said second antibody or antibody fragment to said marker-specific primary antibody or antibody fragment is from about 5 to about 40.

Claim 19

The method of either of claims 1 or 4, wherein said label is a radiolabel, and wherein prior to photoscanning, a second substance is injected into the subject, said second substance being radiolabeled with a radioisotope emitting at a different energy from the marker-specific antibody or antibody fragment label and capable of independent detection by said photoscanning device, the level of activity of said second substance being use to determine the background activity due to non-targeted specific antibody or antibody fragment, said background activity being subtracted from the total activity of the specific antibody or antibody fragment, whereby the activity of substantially only the targeted antibody or antibody fragment is determined.

Claim 21

The method of either of claims 1 or 4, wherein at least one of said labeled primary antibody or antibody fragment and said second antibody or antibody fragment is whole IgG.

Claim 22

The method of either of claims 1 or 4, wherein said second antibody is whole IgG or IgM.

Claim 23

The method of either of claims 1 or 4, wherein the molar ratio of said second antibody or antibody fragment to said labeled marker-specific primary antibody or antibody fragment is from about 5 to about 40.